Discovery of a dual-acting inhibitor of interleukin-1β and STATs for the treatment of inflammatory bowel disease-Reference-Cited by-同舟云学术

Discovery of a dual-acting inhibitor of interleukin-1β and STATs for the treatment of inflammatory bowel disease

Published:2024 Issue:1 Volume:15 Page:193-206
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Cai Haowei¹,Liu Zhuorong¹,Sun Ping¹,Zhou Yinghua¹,Yan Yuyun¹,Luo Yiming¹,Zhang Xiuxiu¹,Wu Ruiwen¹,Liang Xiangting¹,Wu Dan¹,Hu Wenhui¹,Yang Zhongjin¹^ORCID

Affiliation:

1. Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China

Abstract

Hybridization of active fragments led to the NLRP3-based dual inhibitor 10v, which exhibited potent inhibitory activity against the IL-1β and STAT pathway.

Funder

Guangzhou Municipal Science and Technology Project

National Natural Science Foundation of China

Government of Guangdong Province

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D3MD00451A

Reference28 articles.

1. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries

2. Ulcerative colitis

3. Crohn's disease

4. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease;Cytokine & Growth Factor Reviews;2024-10